Gemcitabine, a rare cause of chemotherapy-related reticulate hyperpigmentation
https://doi.org/10.4081/dr.2024.9872
HTML: 1
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Reticulate pigmentary disorders can be classified into inherited or acquired and cutaneous drug-induced reticulate hyperpigmentation belongs to this last group. The list of the drugs involved is constantly increasing and chemotherapy agents are frequently implicated. We report a new case of chemotherapy-related reticulate hyperpigmentation to gemcitabine, even though a previous chemotherapy with nanoparticle, albumin-bound (Nab®) paclitaxel and gemcitabine may have promoted the onset of the disease. Reassurance of the patients is important in these cases, in order to continue the chemotherapy, and gradual fading of the hyperpigmentation is usually observed, as in our case.
Sibaud V, Fricain JC, Baran R, et al. Anomalies pigmentaires induites par les traitements anticancéreux. Première partie: les chimiothérapies [Pigmentary disorders induced by anticancer agents. part I: chemotherapy]. Ann Dermatol Venereol. 2013;140:183-96.
Masson Regnault M, Gadaud N, Boulinguez S, et al. Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature. Dermatology. 2015;231:312-8.
Puri PK, Lountzis NI, Tyler W, et al. Hydroxychloroquineinduced hyperpigmentation: the staining pattern. J Cutan Pathol. 2008;35:1134-7.
Sanke S, Mendiratta V, Jassi R, et al. Rituximab induced reticulate pigmentation over face in pemphigus vulgaris. Dermatol Ther. 2020;33:e13752.
Cohen PR. Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation. World J Clin Cases. 2016;4:390-400.
Necessary CA, Roffwarg D, Ellis D. Reticulated hyperpigmentation following chemotherapy for radiation-induced osteosarcoma. J Am Acad Dermatol. 2014;71:e23-4.
Youssef M, Mokni S, Belhadjali H, et al. Cyclophosphamide-induced generalised reticulated skin pigmentation: a rare presentation. Int J Clin Pharm. 2013;35:309-12.
Kumar S, Bhattacharjee R, Kambhampati SBN, et al. Chemotherapy-induced reticulate pigmentation in three Indian patients including a case in the pediatric age group. Indian J Dermatol Venereol Leprol. 2021;87:386-388.
Allen BJ, Parker D, Wright AL. Reticulate pigmentation due to 5-fluorouracil. Int J Dermatol. 1995 Mar; 34:219-20.
Jogi R, Garman M, Pielop J, et al. Reticulate Hyperpigmentation secondary to 5-fluorouracil and idarubicin. J Drugs Dermatol. 2005;4:652-6.
Wright AL, Bleehen SS, Champion AE. Reticulate pigmentation due to bleomycin: light- and electron-microscopic studies. Dermatologica. 1990;180:255-7.
Kang D, Kim N, Im YH, et al. Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial. J Am Acad Dermatol. 2022;87:858-860.
Chu CH, Chou CY, Lin FL. Generalized eczema craquelé (asteatotic dermatitis) associated with pemetrexed treatment. J Eur Acad Dermatol Venereol. 2016;30:e81-e83.
Ethics Approval
Cutaneous adverse eventsCopyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
